

EACR

European Association
for Cancer Research

CONFERENCES

www.eacr.org

EACR Conference

Defence is the Best Attack

Immuno-Oncology Breakthroughs

13-15 May 2025 | Barcelona, Spain

Scientific Programme Committee

Joan Seoane
Josep Tabernero
Yardena Samuels

Ignacio Melero
Sonia Guedan



Scan the QR code to access online conference resources, including speaker and poster abstracts

eacr.org/conference/defenceisthebestattack2025

**Please be patient, the website may load slowly*

EACR onsite team



Hannah Barrs
Conference Officer



Kathryn Wass
Programmes Manager



Jane Smith
Chief Executive Officer



Sam Kirk
Communications and
Social Media Coordinator

Conference dinner

Optional ticketed event, Wednesday 14 May, 20:30

The conference 'buffet' dinner will take place on the Wednesday night in the Flooded Forest at CosmoCaixa. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment.

It is important that you bring your participant badge with you for entry to the dinner.



EACR European Association
for Cancer Research

EARLY CAREER RESEARCHERS' CONFERENCE

Virtual event | 24 - 25 June 2025

eacr.org/conferences

9 top speakers including:

Kevin Ryan
Elisa Panada
Joan Chang

Ultan McDermott
Thomas Lemberger
Maria Rescigno

A must-attend for early-career cancer researchers

Covering the burning questions of young scientists that are transitioning from their PhD or postdoc and the options available in academia and beyond.

- Leadership skills
- Career development - to academia, industry, or editorial positions
- Making your research translatable, moving from a clinic to the lab
- How to fund your research
- The value of open science

16 top speakers including:

Valerie Weaver
Michael Milone
Peter Friedl

Sara Wickstrom
Frances Balkwill
Emmanuel Donnadieu

New bigger venue for this popular conference

Covering cutting-edge, multidisciplinary efforts to create models that mimic the complexity of tissue formation, tissue homeostasis, and the dysregulation of these processes during cancer.

- Targetable roles of the extracellular matrix in cancer biology
- Cancer immunotherapies
- Advanced imaging technologies
- Organoids and microtissue platforms
- Spatial transcriptomics

EACR Conference

GOODBYE FLAT BIOLOGY:

ex vivo to in vivo models of cancer

23 - 25 September 2025, Essen

eacr.org/conferences

EACR Conference

CANCER NEURO- SCIENCE

14 - 16 October 2025, Bilbao

eacr.org/conferences

16 top speakers including:

Doug Hanahan
Leanne Li
Claire Magnon

Erica Sloan
Frank Winkler
Sebastien Talbot

Bringing together global leaders in this exciting and rapidly evolving field

Identifying the most relevant current insights, and developing a roadmap for future preclinical, translational and clinical research.

- Neural influences on cancer cells
- Neural influences on the tumor environment
- Influences of cancer (therapies) on the nervous system
- Cancer-intrinsic neural mechanisms

13 top speakers including:

Alberto Bardelli
Andrew Biankin
Yin Cao

Selma Masri
Shuji Ogino
Jelle Wesseling

Shaping the future of early-onset cancer research

Providing a unique platform to discuss the latest discoveries, promoting interdisciplinary collaboration, and identifying strategies for early detection, prevention, and treatment

- Systems and translational cancer epidemiology
- Molecular pathological epidemiology
- Precision-based cancer prevention/control strategies
- Molecular features of early-onset cancers
- Biological basis for cancer disparity

EACR-Mark Foundation for Cancer Research Joint Conference

THE RISE OF EARLY-ONSET CANCERS

Biology, Causes and Detection

11 - 13 November 2025, Bergamo

eacr.org/conferences

Defence is the Best Attack: Immuno-Oncology Breakthroughs

Tag us   @helloeacr | Wi-Fi: EVENTOS_COSMOCAIXA_BCN Password: asistente@

Day 1 | Tuesday 13 May

Session 1
posters can be
put up

From 11:30

REGISTRATION

12:30-13:30

WELCOME REFRESHMENTS

A chance to meet fellow attendees and enjoy a light buffet

13:30-13:40

CONFERENCE WELCOME

Scientific Programme Committee

13:40-14:00

SESSION 1 Chair: Joan Seoane

Myriam Chalabi NKI, Netherlands

Q&A: 14:00-14:10

'Neoadjuvant immunotherapy in pMMR and dMMR colorectal cancers'

14:10-14:30

Marcela Maus Harvard University, USA

Q&A: 14:30-14:40

'Driving new CAR T cells'

14:40-15:00

THE EMBO KEYNOTE LECTURE

Q&A: 15:00-15:10

Ido Amit Weizmann Institute of Science, Israel

'Leveraging single cell technologies to engineer the immune system'

15:10-15:40

COFFEE BREAK AND SOLO MEET-UP

Solo travellers are invited to meet up at the EACR banner to connect with fellow adventurers

15:40-16:00

QIAGEN SYMPOSIUM

Q&A: 16:00-16:10

Gwenann Cadiou INCIT, France

'Optimizing tumor reactivity and functions of therapeutic T cells'

16:10-16:40

KEYNOTE LECTURE

Q&A: 16:40-16:55

Antoni Ribas UCLA, USA

'Multicellular interactions mediating response and resistance to cancer immunotherapy'

16:55-17:15

Omer Dushek University of Oxford, UK

Q&A: 17:15-17:25

'Optimising CAR-T cell sensitivity by engineering extracellular sizes'

17:25-18:30

5 PROFFERED PAPERS *see index on page 10*

18:30-19:30

 WELCOME BUFFET AND DRINKS

19:30-21:00

POSTER DISCUSSION SESSION 1

Presenters of posters 1-101 should stand by their boards.

Day 2 | Wednesday 14 May

08:00-08:30

 EARLY POSTER VIEWING WITH COFFEE

SESSION 2 Chair: Yardena Samuels

08:30-09:30

5 PROFFERED PAPERS *see index on page 10*

09:30-09:50

Johanna Joyce University of Lausanne, Switzerland

Q&A: 09:50-10:00

'Exploring and therapeutically exploiting the tumour microenvironment'

10:00-10:20

Joan Seoane VHIO, Spain

Q&A: 10:20-10:30

'Impact of the tumor microenvironment on immunotherapies targeting brain cancer'

10:30-10:50

Maria Casanova-Acebes CNIO, Spain

Q&A: 10:50-11:00

'Circadian immunity: can we exploit it therapeutically?'

11:00-11:30

 COFFEE BREAK

11:30-11:50

CELL SIGNALING TECHNOLOGY SYMPOSIUM

Q&A: 11:50-12:00

Maxime Jacquet Cell Signaling Technology

'Advancing Cancer Research with CST's Solutions: A Spotlight on CAR T Therapies and Emerging Technologies'

12:00-13:00

5 PROFFERED PAPERS *see index on page 10*

13:00-14:00

 LUNCH BREAK

light refreshments will be served

Take down
session 1
posters

Session 2
posters can be
put up

SESSION 3 Chair: Sonia Guedan

14:00-14:30

KEYNOTE LECTURE

Q&A: 14:30-14:45

Alberto Mantovani Humanitas University, Italy

'The yin yang of tumour-associated macrophages'

14:45-15:05

Filipe Pereira Lund University, Sweden

Q&A: 15:05-15:15

'In vivo dendritic cell reprogramming for cancer immunotherapy'

15:15-15:35


Yardena Samuels Weizmann Institute of Science, Israel

Q&A: 15:35-15:45



'Revisiting the neoantigen approach to cancer immunotherapy'

15:45-16:15

 COFFEE BREAK

16:15-17:00	PANEL DISCUSSION: MECHANISMS OF ACQUIRED RESISTANCE TO IMMUNOTHERAPIES Joan Seoane (VHIO, Spain), Sonia Guedan (Clinic Barcelona, Spain), Ignacio Melero (Cima Universidad de Navarra, Spain), Yardená Samuels (Weizmann Institute, Israel), Josep Taberneró (VHIO, Spain)
17:00-18:00	5 PROFFERED PAPERS <i>see index on page 11</i>
18:00-19:30	POSTER DISCUSSION SESSION 2 <i>Presenters of posters 102-158 (+68 & 92) should stand by their boards</i>
19:30	OPTIONAL CONFERENCE DINNER  <i>The conference dinner will be held at the atmospheric flooded forest within CosmoCaixa (separate ticketed event).</i>

Day 3 | Thursday 15 May

08:00-08:30	 EARLY POSTER VIEWING WITH COFFEE
	SESSION 4 Chair: Ignacio Melero
08:30-09:30	5 PROFFERED PAPERS <i>see index on page 11</i>
09:30-09:50 Q&A: 09:50-10:00	Sonia Guedan IDIBAPS, Spain 'Advancing CAR-T cell therapy: Innovations for solid tumors and hematologic malignancies'
10:00-10:20 Q&A: 10:20-10:30	THE SITC LECTURE Christopher Klebanoff Memorial Sloan Kettering Institute, USA 'Therapeutic targeting of human cancers using CD4+ T cells'
10:30-10:50 Q&A: 10:50-11:00	Rony Dahan Weizmann Institute of Science, Israel 'Dendritic-T cell crosstalk in driving anti-tumor immunity and immunotherapy'
11:00-11:30	 COFFEE BREAK
11:30-12:00 Q&A: 12:00-12:15	KEYNOTE LECTURE Tak Mak Princess Margaret Cancer Centre, Canada 'Metabolic and neural regulation of immunity and cancer'
12:15	SUMMARY, AWARDS AND DEPART

GET
UPDATES:
eacr.org/congress

Annual Congress of the

EACR 2025

16 - 19 June | Lisbon

Innovative Cancer Science

European Association for Cancer Research



**OUTSTANDING
SCIENCE IN A
WELCOMING
ENVIRONMENT**



**GREAT NETWORKING
OPPORTUNITIES
WITH 2000+ CANCER
RESEARCHERS**



**98% OF
PARTICIPANTS
WOULD
RECOMMEND**

SESSION TOPICS INCLUDE:

- Advanced *in vitro* Models
- AI Tools in Cancer Research
- Brain Metastasis
- Cancer Genomics
- Cancer Therapy Resistance
- Clinical Cancer Biomarkers
- DNA Repair and Immunosurveillance
- Early Onset Cancers
- New Drugs on the Horizon
- Next Generation Immunotherapy Modalities
- Non-invasive Diagnostics
- Novel Models of Cancer Cachexia
- Organ-specific Metastasis
- Prevention and Early Detection
- RNA Biology in Cancer
- Tumour Dormancy
- Tumour Innervation

Travel grants

More information about EACR grants: eacr.org/travel-grant

Congratulations to the recipients of the travel grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

EACR-Worldwide Cancer Research Travel Grants provide funds to help early-career EACR members and members based in low- or middle-income economy countries to participate in our conferences.

CANDELARIA AGUILAR GARCÍA SPAIN
JAVIER ARROYO RÓDENAS SPAIN
CATARINA AZEVEDO PORTUGAL
DEPANSHI PANDIT INDIA
LILI SZABO GERMANY
MANOLYA YILDIZ TURKEY

**worldwide
cancer
research**

EACR
European Association
for Cancer Research

A number of travel grants have also been awarded by **EFIS-EJI** to help early-career researchers who need financial assistance to attend the conference and present their work as an oral or poster presentation.

KRISTINA DRAGANIC AUSTRIA
LEESA LERTSUMITKUL AUSTRALIA

 **efis** European Federation of
Immunological Societies

**European Journal of
Immunology**
Basic · Clinical · Translational

Supporters

QIAGEN

Website: www.qiagen.com

Represented at the conference by:

Samuel Rulli, Gwenann Cadiou, Erhan Nas

Symposium: Tuesday 13 May | 15:40-16:10

Gwenann Cadiou (INCIT, France)

'Optimizing tumor reactivity and functions of therapeutic T cells'



Cell Signaling Technology

Website: www.cellsignal.com

Represented at the conference by:

Maxime Jacquet, Stephane Moal


Symposium: Wednesday 14 May | 11:30-12:00

Maxime Jacquet (Cell Signaling Technology)


'Advancing Cancer Research with CST's Solutions: A Spotlight on CAR T Therapies and Emerging Technologies'



Our thanks to the following partners for supporting us in promoting this conference:



We would also like to thank the following grant providers:



This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.

Proffered paper and poster index

View abstracts when logged in at www.eacr.org/conference/persistercells2025

Proffered papers session 1: Tuesday 13 May, 17:25 | Also as posters on Tuesday

1 Engineering TCR-controlled Fuzzy Logic into CAR T-Cells Enhances Therapeutic Specificity Presented by Sooraj Achar, University of Oxford, UK and National Cancer Institute, Bethesda, MD, USA

2 Unveiling the role of neutralizing antibodies as complementary effectors in oncolytic adenovirus immunotherapy Presented by Victor Arias, University of Helsinki, FINLAND

3 Reprogramming CD8+ T cell branched N-glycosylation limits exhaustion, enhancing cytotoxicity and tumor killing: impact in cancer immunotherapy. Presented by Catarina Azevedo, School of Medicine and Biomedical Sciences (ICBAS) and Institute for Research and Innovation in Health (i3S), University of Porto, PORTUGAL

4 Refining Immunotherapy Response Prediction in Advanced Bladder Cancer Presented by Lilian Marie Boll, Hospital del Mar Research Institute (HMRIB), Barcelona, SPAIN

5 Armoured-CAR T cell-redirecting immunotherapy for metastatic and refractory Ewing Sarcoma Presented by Clara Bueno, Josep Carreras Leukemia Research Institute, Barcelona and CIBERONC, Instituto de Salud Carlos III, Madrid, SPAIN

Proffered papers session 2: Wednesday 14 May, 08:30 | Also as posters on Wednesday

8 Evaluating Immunotherapy Responses in Glioblastoma Through Patient-Derived Tumor Tissue Cultures (PDTTCs) Presented by Laura Carrillo-Bosch, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

9 MYC Inhibition Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC Presented by Silvia Casacuberta Serra, Peptomyc S.L., Barcelona, SPAIN

10 Novel replication repair-deficient glioma mouse model provides insight and preclinical basis for immunotherapies Presented by Owen Crump, Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, CANADA

11 Sequential treatment strategies to increase sensitivity of multiple myeloma cells to BCMA CAR T cells Presented by Marta Cuenca, UMC Utrecht, NETHERLANDS

12 Priming the Aggressive TAM Subset: Investigating TSP1-Driven Macrophage Polarization in Colorectal Cancer Presented by Kristina Draganic, Medical University of Vienna, AUSTRIA

Proffered papers session 3: Wednesday 14 May, 12:00 | Also as posters on Wednesday

13 CD44v6-Specific CAR-NK Cells: A Novel Approach to Precision Medicine in Bladder Cancer Presented by Marta Dueñas Porto, CIEMAT Madrid and Fundación de Investigación Biomédica Hospital 12 de Octubre, Madrid, SPAIN

14 Fractioned radiotherapy empowers TCR/CAR-T cells in preclinical settings and reveals immunomodulatory properties in prostate cancer patients Presented by Filippo Folchini, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, ITALY

15 Epitranscriptomics in CD8+ T Cells: A New Layer of Immune Regulation Presented by Iosifina Foskolou, Sanquin Research and Landsteiner Laboratory Amsterdam UMC, Amsterdam, NETHERLANDS

16 Understanding the Role of Leukemia Inhibitory Factor (LIF) in the Bone Metastatic Microenvironment Presented by Cayetano Galera, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

17 Exploiting circulating lymphocytes and cell-free DNA as a source to develop minimally-invasive personalized T-cell therapies Presented by Andrea Garcia, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

Proffered papers session 4: Wednesday 14 May, 17:00 | Also as posters on Wednesday

6 A Heterologous Prime-Boost Strategy using RUTI Vaccine to Improve the BCG Response in Non-Muscle-Invasive Bladder Cancer Patients (RUTIVAC-1 Trial) Presented by Cecilia Cabrera, Irsicaixa Foundation and The Institute for Health Science Research Germans Trias i Pujol (IGTP), Barcelona, SPAIN

7 Harnessing the synaptic synergy between T cell receptor and Interleukin-2 receptor for cancer immunotherapy Presented by Jesusa Capera, The Kennedy Institute of Rheumatology, University of Oxford, UK

18 Inhibition of nonsense mediated mRNA decay induces tumour immunosurveillance and reduces growth of hypermutated tumours Presented by Ana Janic, Universidad Pompeu Fabra (UPF), Barcelona, SPAIN

19 Neoantigen based mRNA LNP Vaccine for Cancer Immunoprevention in Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome Presented by Sunam Mander, The Hospital for Sick Children (SickKids), Toronto, CANADA

20 Replication repair deficient isocitrate dehydrogenase mutant gliomas have a unique genomic and immune profile resulting in favorable response to combination immune and targeted therapy Presented by Vienna Mazzoli, The Hospital for Sick Children and the University of Toronto, Toronto, CANADA

Proffered papers session 5: Thursday 15 May, 08:30 | Also as posters on Wednesday

21 A role for IL-1 family cytokines and T cell receptor activation signals in propagating stem-like T cell phenotypes with potent anti-tumour activity. Presented by Dane Newman, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA

22 Spatial biomarkers of response to neoadjuvant therapy in muscle-invasive bladder cancer: the DUTRENEO trial Presented by Eduard Porta Pardo, Josep Carreras Leukaemia Research Institute and Barcelona Supercomputing Center, Barcelona, SPAIN

23 Hypoxia shapes Tumor Immune Microenvironment Through Cell-Type Dependent Responses in Diffuse Astrocytomas Presented by Aliisa Tiihonen, Prostate Cancer Research Center, Tampere University and TAYS Cancer Center, Tampere University Hospital, Tampere, FINLAND

24 H-SPOT: High-Throughput Screening for Public Oncogenic Targets for T-Cell Therapy Presented by Anna Yuste Estevanez, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

25 Circulating TIM-3 levels are associated to CDK4/6i therapeutic response in HR+/HER2- Advanced Breast Cancer Presented by Eudald Felip, Institut Catala Oncologia and IrsiCaixa, Badalona, SPAIN (not presented as a poster)

Poser presentations session 1: Tuesday 13 May, 19:30-21:00

- 26 Boosting Antitumor Immunity in Glioblastoma: The Impact of ILT2 and IFN-Signaling Presented by Candelaria Aguilar Garcia, Departamento de Biología Funcional Immunología, Universidad de Oviedo and Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Asturias, SPAIN
- 27 Unraveling the crosstalk between stem cells and macrophages in the healthy and leukemic bone marrow niche Presented by Philipp Aktories, Faculty of Biology and Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY
- 28 Ex vivo functional validation of neoantigens using an autologous dendritic cell-naïve CD8+ T Cell co-culture assay Presented by Júlia Albó Delgado, IrsiCaixa, Badalona, SPAIN
- 29 Tumor-associated fibroblast-dependent immunosuppression in NSCLC and its potential reversion with the antifibrotic drug Nintedanib Presented by Jordi Alcaraz Casademunt, Universitat de Barcelona and CIBERES, Instituto de Salud Carlos III, Madrid, SPAIN
- 30 Oncostatin M in the pre-tumour niche: Computational insights into fibrosis-inflammation crosstalk in HCC Presented by Uxue Alvarez Huesa, Biogipuzkoa Health Research Institute, Donostia, Gipuzkoa, SPAIN
- 31 DANCR's Role in Melanoma Progression and Immune Resistance Presented by Ege Amirak, Izmir Institute of Technology, TURKEY
- 32 Unraveling RNA modification dynamics in prostate cancer progression and immune interactions at single-cell resolution Presented by Ana Macrina Añazco Guenkova, CSIC-USAL and IBSAL, Salamanca, SPAIN
- 33 CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell Acute Lymphoblastic Leukemia progression Presented by Javier Arroyo Ródenas, Hospital Universitario 12 de Octubre and CNIO, Madrid, SPAIN
- 34 Teneurin 4: A Key Driver of Colorectal Cancer Progression and a Novel Therapeutic Target Presented by Zobia Arshad, Department of Molecular Biotechnology and Health Sciences, University of Torino, ITALY
- 35 Fc-optimized G1TR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote anti-tumor immunity Presented by Yahel Avraham, Weizmann Institute of Science, Rehovot, ISRAEL
- 36 High-resolution immuno-profiling and spatial analysis deciphers TME niches associated with prognosis in CRC. Presented by Raquel Bartolome-Casado, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, NORWAY
- 37 Aberrant collagen turnover as a potential driver of immunosuppression in lung adenocarcinoma Presented by Victoria Batto, University of Barcelona and Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Barcelona, SPAIN
- 38 Identification of human immunogenic neoantigens using in silico prediction coupled to ex vivo functional validation Presented by Cristina Benitez, IrsiCaixa, Badalona, SPAIN
- 39 Patient-Derived lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma Presented by Christine Bezombes, Centre de Recherches en Cancérologie de Toulouse. INSERM, CNRS, Université de Toulouse, FRANCE
- 40 Antitumor activity and toxicity of anti-4-1BB agonistic antibodies Presented by Jasmine Blanga, Weizmann Institute of Science, Rehovot, ISRAEL
- 41 Development of senolytic CAR T cell therapies for the treatment of solid tumors Presented by Marta Bort Brusca, Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, SPAIN

- 42 Genetic Insights into Immune Regulation in Asthma and Lung Cancer: Implications for Immunotherapeutic Targeting Presented by Matthew Boyton, University of Bristol, UK
- 43 Tissue-Resident Alveolar Macrophages as key mediators of pulmonary antimetastatic immunity Presented by Claudia Mariela Brenis Gomez, Inflammation Research Center VIB-Ugent and Gent University, Gent, BELGIUM
- 44 PD-1 and BTLA inhibit T cell activation with and without co-stimulation Presented by Sofia Bustamante Eguiguren, University of Oxford, UK
- 45 Generation and characterization of ovarian cancer organoids to explore tumor-immune interactions Presented by Sara Bystrup, Germans Trias i Pujol Research Institute, Badalona, SPAIN
- 46 Dysregulated T-cell Dynamics and TCR Repertoire Alterations determine CDK4/6i efficacy and improved antitumor response Presented by Sara Cabrero de las Heras, IrsiCaixa AIDS Research Institute and Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, SPAIN
- 47 Cytokine secretion plasticity in MDR human leukemic cells and signaling pathways involved in the resistance-immunity crosstalk Presented by Paula Cadenas, University of Murcia, SPAIN
- 48 Tumor-specific antigens derived from microproteins as cancer vaccine candidates Presented by Marta E. Camarena, Hospital del Mar Research Institute, Barcelona, SPAIN
- 49 Neutrophils physically interact with tumor cells to form a signaling niche promoting breast cancer aggressiveness Presented by Sandra Camargo, Tel Aviv University, ISRAEL
- 50 Towards precision medicine: New experimental approaches to analyze the effects of TGF- inhibitors in hepatocellular carcinoma. Presented by Ana Cantos Cortés, IDIBELL, L'Hospitalet de Llobregat, Barcelona and CIBEREHD, Instituto de Salud Carlos III, Madrid, SPAIN
- 51 Association between circulating low density neutrophils (LDNs) and resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): proteomic characterization and circulating inflammatory profile. Presented by Natalia Castro Unanua, Navarrabiomed-IdiSNA, Pamplona, Navarra, SPAIN
- 52 Investigate the therapeutic effect of immune cell therapy in the tumor microenvironment Presented by Yun-Hsuan Chang, RIKEN, Yokohama city, JAPAN
- 53 Macrophages regulate PD-1 and CTLA-4 expression on ILC2 and their responsibility in the tumor microenvironment Presented by Cecilia Ciancaglini, Tumor Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, ITALY
- 54 CRISPR-Cas9 based interrogation of the T cell kinase and phosphatase network reveals novel mediators of inhibitory signalling through PD-1 and BTLA Presented by Joseph Clarke, WIMM, University of Oxford, UK
- 55 Emotional distress and perceived health related to the response to immune checkpoint inhibitors therapy Presented by Miri Cohen, University of Haifa, ISRAEL
- 56 Inducing antitumor responses through embryonic stem cells Presented by Magda Correia, iBiMED, University of Aveiro, PORTUGAL
- 57 Unravelling tumor-intrinsic resistance mechanisms to T-cell mediated cytotoxicity in pancreatic cancer Presented by Judit Gomez, CIC bioGUNE, Bizkaia Technology Park, Bizkaia, SPAIN
- 58 The blueprint of HLA-I presentation for all human missense variants and its contribution to immunoeediting in cancer genomes Presented by Ana Dueso-Barroso, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

- 59 lncRNA NRAV Negatively Regulate Some ISGs under Type-I and Type-II IFN Treatment in Melanoma Presented by Kadir Ziya Durmuş, Izmir Institute of Technology, Izmir, TURKEY
- 60 The secretome of tumor-activated fibroblasts modulates the expression pattern of mitochondrial respiration and human leukocyte antigen system related genes in melanoma cells Presented by Jokin Eguia Sanchez, University of the Basque Country (UPV/EHU), Bizkaia, SPAIN
- 61 Exploring the function of integrin CD11b on T cells and its interaction with Siglec-15 in the context of cancer immunosuppression Presented by Jone Etxaniz, CICbioGUNE, Bilbao, SPAIN
- 62 CD28 CAR T Cells as a Novel Treatment Option for T-Cell Malignancies Presented by Julian Faerber, University of Freiburg and Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, GERMANY
- 63 The Glycoimmuno-Code in Colorectal Cancer: Glycans as a New Class of Immune Checkpoints Presented by Angela Fernandes, Institute for Research and Innovation in Health (i3S), University of Porto, PORTUGAL
- 64 Analysis of the alterations in the Blood-Brain Barrier and the immunological profile of gliomas induced by the Engineered Tumor Necrosis Factor-alpha Presented by Andrés Fernández, Instituto de Salud Carlos III, Madrid, SPAIN
- 65 Study of putative lncPEPs presented by HLA-I in epithelial tumor cells isolated from Epithelial Ovarian Cancer Presented by Anahir Franco Gacio, CICA, Universidad de A Coruña (UDC) and Instituto de Investigación Biomédica de A Coruña (INIBIC), SPAIN
- 66 Dual Engagement: Harnessing NK and T Cell Cytotoxicity via CD3, CD16 Bispecifics and an IL-2 Variant Presented by Max Freihammer, Uniklinik Köln, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, GERMANY
- 67 Induction of macrophage-mediated phagocytosis of prostate cancer cells upon gene therapy in a microfluidic 3D model Presented by Nadine Gimenez de Assis, University of São Paulo School of Medicine, São Paulo, BRAZIL and Radboud University Medical Center, Nijmegen, NETHERLANDS
- 69 An integrated single-cell atlas of the ccRCC tumor microenvironment identifies prognostic EMT-related malignant subpopulations shaping an immune-evasive, pro-angiogenic tumor microenvironment. Presented by Samuel Garcia Esteve, Hospital Clínic Barcelona (Institut del Càncer i Malalties de la Sang - ICAMS) and Universitat de Barcelona, SPAIN
- 70 Generation of a dual CAR-T cell therapy for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T-ALL/LL) Presented by Alba Garcia Pérez, One chain Immunotherapeutics S.L., Barcelona, SPAIN
- 71 DEF6 promotes canonical CD56dim NK cell survival and function Presented by Lars Gerullat, Karolinska Institute, Stockholm, SWEDEN
- 72 Role of IDO1 inhibitor in enhancing CD4+ T-cell migration towards cancer cells in head and neck squamous cell carcinoma Presented by Martina Giacomini, University of Helsinki, FINLAND
- 73 HT29 colon cancer cell spheroid co-culture system to study migration of THP-1-derived macrophages Presented by Roben Gieling, Northumbria University, Newcastle upon Tyne, UK
- 74 Therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes Presented by Iñigo González Larreategui, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN
- 75 Cartilage oligomeric matrix protein: a novel modulator of anti-tumor immunity Presented by Gilar Gorji Bahri, Lund University, Malmö, SWEDEN

76 Overcoming immunotherapy resistance: a novel platform to reverse T cell exhaustion in vitro Presented by Rebecca Graham, Cancer Research Horizons, Francis Crick Institute, London, UK

77 Engineering p95HER2 CAR T cells for the treatment of HER2-positive tumors Presented by Ariadna Grinyo-Escuer, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, Barcelona, SPAIN

78 Adipose tissue T cell niche contains resident memory T cells that cross talk with developing tumors and possess potential anti-tumor function Presented by Aikaterini Chatziioannou, National and Kapodistrian University of Athens and Institute for Clinical Chemistry and Laboratory Medicine, TU Dresden, Dresden, GREECE

79 Unsupervised clustering reveals noncanonical myeloid cell subsets in the brain tumor microenvironment Presented by Ismail Hermelo, Prostate Cancer Research Center, Tampere University and Tampere University Hospital, Tampere, FINLAND

80 Immune profiling of the tumor microenvironment for optimizing Treg-targeted antibody-based immunotherapy Presented by Ella Herzog, Weizmann Institute of Science, Rehovot, ISRAEL

81 Exercise effects on markers of immune function in patients with metastatic breast cancer: the PREFERABLE-EFFECT study Presented by Elisa Heyrman, Karolinska Institutet, Stockholm, SWEDEN

82 T Cells in the Treatment of Hematological Malignancies Presented by Jovana Ilic, Paracelsus Medical University, Clinic Nuremberg, Nuremberg, GERMANY

83 Patient-derived tumor tissue cultures (PDTTCs) as a new platform for assessing T cell engager efficacy in glioblastoma. Presented by Raffaella Iurlaro, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

84 Immune-Metabolic Shift Associated with High-Risk Disease Relapse in Multiple Myeloma Presented by Mara John, Mildred-Scheel Early Career Center (MSNZ), University Hospital Würzburg, GERMANY

85 Unlocking NK Cell Potential by Inhibition of PSMB9 Presented by Asli Kasapoglu, Swiss Institute for Experimental Cancer Research, EPFL and Swiss Cancer Center Léman, Lausanne, SWITZERLAND

86 Unraveling the Role of MicroRNA-142 in Melanoma Progression and Tumor Immunity Presented by Hilal Kayacan, Izmir Institute of Technology, Urla, Izmir, TURKEY

87 Deciphering the novel ZRF1-S100A9-Neutrophil interplay in breast cancer metastasis via paracrine signaling Presented by Aysegul Kaymak Ozdemir, Ege University, Izmir, TURKEY

88 TCR-T cells targeting Minor Histocompatibility antigens for the Treatment of Hematological Malignancies Presented by Nafiseh Keshavarzian, Université de Montréal and Hopital Maisonneuve-Rosemont Research Centre, Montreal, CANADA

89 LAG-3 blockade enhances the anti-tumor efficacy of PD-1 blockade combined with radiotherapy in a syngeneic murine triple-negative breast cancer model Presented by In Ah Kim, Seoul National University Bundang Hospital, Seongnam and Seoul National University, SOUTH KOREA

90 Treatment efficacy of antibody-drug conjugates in testicular germ cell tumour cells Presented by Lucia Kucerova, Comenius University and National Cancer Institute, Bratislava, SLOVAK REPUBLIC

91 PARP inhibitors as immune modulators in metastatic ovarian cancer therapy Presented by Irena Kusova Moserova, Sotio Biotech a.s., Prague, CZECH REPUBLIC

93 Impact of pancreatic ductal adenocarcinoma mutational heterogeneity on mechanisms of immune evasion and mutation-specific therapeutic vulnerabilities Presented by Gabija Lazaraviciute, University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, UK

94 EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses Presented by Leesa Lertsumitkul, The Walter and Eliza Hall Institute of Medical Research and The University of Melbourne, Victoria, AUSTRALIA

95 A novel regulatory T cell subset predicts prognosis and recurrence in breast cancer Presented by Antonietta Liotti, CNR/IEOMI and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, ITALY

96 LIF promotes immunosuppression through C1q+ TAMs in GBM Presented by María López Vázquez, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

97 Study of tumor-associated macrophage targeted therapy with two myeloid depleting agents utilizing a novel patient-derived organoid xenograft model in esophageal squamous cell carcinoma Presented by Bryan Lung, The University of Hong Kong, Pokfulam, HONG KONG

98 Tumor-mimicking flagellin-derived peptides from gut commensals modulate T-cell response to melanoma during anti-PD1 immunotherapy Presented by Angeli Dominique Macandog, Istituto Europeo di Oncologia, Milan, ITALY

99 IMiDs and CELMoDs enhance antigen presentation via MHC I on the surface of Myeloma cells - a potential novel immunostimulatory effect Presented by Shannon Martin, Institute of Cancer Research, London, UK

100 Proliferative fraction of leukemic cells shows enhanced LILRB4 expression in chronic lymphocytic leukemia: implications for migration and immune evasion. Presented by Alejandra Martínez Pérez, Universidad de Oviedo and Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, SPAIN

101 Epigenetics Influences the Immune Checkpoint Inhibitor Response in Advanced NSCLC Presented by Mónica Martínez Fernández, IIS Galicia Sur, Vigo, SPAIN

Poser presentations session 2: Wednesday 14 May, 18:00-19:30

68 Targeted Immunotherapy with Anti-HVEM Monoclonal Antibody: A New Hope for Solid Tumors Presented by Gilli Galore Haskel, 4C Biomed Services Ltd., Netanya, ISRAEL

92 Evaluating the role of circulating myeloid cells as biomarkers for immunotherapy response in solid tumors, focus on low density neutrophils and their phenotype Presented by Ibone Labiano, Navarrabiomed-IdiSNA, Pamplona-Iruña/Navarra, SPAIN

102 Restoring PARP inhibitor sensitivity through STING activation and NK cell engagement in Homologous Recombination Deficient Breast Cancer Presented by Paula Martínez Sanz, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, SPAIN

103 Taming the metabolism of tumor associated macrophages to fight malignant peripheral nerve tumors Presented by Ionica Masgras, Institute of Neuroscience, National Research Council, Padova, ITALY

104 Superselective Polymeric Nanoparticles for targeting and Engaging T-cells in Glioblastoma Therapy Presented by Elisa Mastrantuono, Gulbenkian Institute for Molecular Medicine and University of Lisbon, Lisbon, PORTUGAL

105 Antitumor effectiveness of gene electrotransfer of mRNA encoding Interleukin-12 in murine colorectal carcinoma and melanoma models Presented by Ajda Medved, Institute of Oncology and University of Ljubljana, Ljubljana, SLOVENIA

106 Epigenetic reset: boosting NK cell function to combat post-surgery tumour recurrence Presented by Henna Mistry, Ottawa Hospital Research Institute and University of Ottawa, CANADA

107 Breaking Barriers in AML Treatment: The Power of Switchable AdCAR T Cells Presented by Nicola Muayad Jabra Mitwasi, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, GERMANY

- 108 Charting immune cell signatures to investigate patient non-response to immunotherapy Presented by Samuel Morabito, Centre Nacional d'Anàlisi Genòmica, Barcelona, Catalonia, SPAIN
- 109 Early immune-stromal interactions shape ovarian cancer metastasis. Presented by Julia Moreno-Vicente, CRUK Cambridge Institute, Cambridge, UK
- 110 Analyzing HLA-I Alterations in Bladder Cancer: From Tumor Tissue to Liquid Biopsy Presented by Alba Navarro Ocon, University of Granada and Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, SPAIN
- 111 Decoding the Fanconi Anemia-Inflammation Axis: A Systems Biology Approach to Pan-Cancer Immunotherapy Vulnerabilities Presented by Depanshi Pandit, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA
- 112 The role of immune checkpoints expressed by monocytes/macrophages in shaping the immunosuppressive ovarian tumor microenvironment Presented by Anna Pawtowska-Lachut, Medical University of Lublin, POLAND
- 113 Engineering BCMA CAR T cells for myeloma-targeted cargo delivery Presented by Victor Peperzak, University Medical Center Utrecht and Utrecht University, NETHERLANDS
- 114 The Role of CCL2 in Bladder Cancer Progression and Metastasis: A Context-Dependent Effect Presented by Mercedes Pérez Escavy, CIEMAT and CIBERONC, Madrid, SPAIN
- 115 Engineering the tumour ecosystem on a chip: a new tool to test cancer immunotherapies Presented by Alice Perucca, IBEC, The Barcelona Institute for Science and Technology (BIST), SPAIN
- 116 Spatial ecosystems of tumor cell states and immune cells shape the efficacy of anti-PD1 immunotherapy in cutaneous melanoma Presented by Félix Pham, Centre Hospitalier Lyon Sud, Lyon 1 University and CRCL, INSERM 1052 - CNRS 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, FRANCE
- 117 Alternatively activated TAMs in the ovarian cancer microenvironment Presented by Bethany Potts, University of Manchester, UK
- 118 Prognostic Significance of the Pre-Treatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis Presented by Ahana Kapuge Dona Varuni Yashodha Ratnayake, University of Helsinki, FINLAND
- 119 Glioma-associated tertiary lymphoid structures are sites of lymphocyte clonal expansion and plasma cell formation Presented by Yvonne Reiss, Goethe University Hospital, Institute of Neurology (Edinger Institute) and Frankfurt Cancer Institute (FCI), Frankfurt, GERMANY
- 120 B7-H6/NKp30 signaling in neuroblastoma: Implications for Prognosis and Immunotherapy Presented by Esther Rey Iborra, Biobizkaia Health Research Institute, Barakaldo, SPAIN
- 121 Identification and characterization of orphan TCRs in CD8 tumor-infiltrating lymphocyte population from epithelial ovarian cancer Presented by Cora Rey Souto, EXPRELA group, CICA - Centro Interdisciplinar de Química e Biología, Universidad de A Coruña (UDC) and INIBIC, A Coruña, SPAIN
- 122 A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses Presented by Juan José Rojas Expósito, IDIBELL and University of Barcelona, Barcelona, SPAIN
- 123 Oncostatin M signalling remodels the immune microenvironment in breast cancer favouring a protumoral inflammation and tumour progression Presented by Ainhoa Romo Valera, Biogipuzkoa Health Research Institute, San Sebastian, SPAIN

- 124 Generation of Dual CD19/CD70 CAR-T Cells for the Treatment of Relapsed Follicular Lymphoma Presented by Maria Ros, IDIBAPS, Barcelona and CIBERONC, Madrid, SPAIN
- 125 Tumor-Immune crosstalk drives invasiveness in triple negative breast cancer (TNBC). Presented by Maria Rosado Sanz, Instituto de Investigación Sanitaria La Fe, Valencia, SPAIN
- 126 Targeting EZH2 to overcome immunotherapy resistance in mCRPC elicits NSD2-dependent anti-tumor immune response Presented by Pilar Salamanca Jiménez, Catalan Institute of Oncology and Oncobell, IDIBELL, Barcelona, SPAIN
- 127 Evolution of TIME under treatment in diffuse astrocytoma tumor relapse and progression Presented by Iida Salonen, Prostate Cancer Research Center, Tampere University and TAYS Cancer Center, Tampere University Hospital, Tampere, FINLAND
- 128 Enhancing Immune Cells via Chemical Modification for Targeted Immunotherapy Presented by Pounami Samadder, Institute of Organic Chemistry and Biochemistry, Prague, CZECH REPUBLIC
- 129 Peptide-driven recombinant receptors for the engineering of anti-cancer living drugs Presented by Elisa Sangiovanni, IRCSS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, ITALY
- 130 Glucocorticoid therapy in hematopoietic stem cell transplantation: effect on immune reconstitution and function in cancer patients Presented by Silvia Santopolo, Bambino Gesù Children's Hospital, Rome, ITALY
- 131 Adrenergic signaling activates the tumor immune microenvironment in Multiple Myeloma Presented by Hatice Satilmis, Vrije Universiteit Brussel, Brussels, BELGIUM
- 132 Reprogramming tumor-associated macrophages with a peptide-drug conjugate for breast cancer immunotherapy Presented by Pablo Scodeller, IQAC-CSIC, Barcelona, SPAIN
- 133 Harnessing neoadjuvant vaccination with viral vectored vaccines to overcome tumor relapse in CPI-resistant model Presented by Laura Secli, Nouscom Srl, Roma, ITALY
- 134 TIM3 Modulation in T Cells and CAR T Cells in Pediatric Relapsed Refractory B-ALL Presented by Jannika Seiferling, Medical Center, University of Freiburg, GERMANY
- 135 Spatio-temporal T cell tracking for personalized TCR-T designs in childhood cancer Presented by Inés Sentis, Centro Nacional de Análisis Genómico, Barcelona, SPAIN
- 136 Allogeneic CAR/TCR Engineered MAIT Cells for Targeting Solid Tumors Presented by Helena Shaked, Pluri Biotech, Haifa, ISRAEL
- 137 Enhanced discriminatory receptors for safe and effective T-cell therapies Presented by Alina Shomuradova, Sir William Dunn School of Pathology, Oxford, UK
- 138 Immune Modulation by LRP1-Targeted Nanoparticles in Healthy and Glioblastoma Donors Presented by Marta Silva, Gulbenkian Institute for Molecular Medicine (GIMM) and Universidade de Lisboa, Lisbon, PORTUGAL
- 139 Targeting PD-L1/PD-1 axis with metabolic inhibitors metformin and 2-deoxy-D-glucose in MDA-MB-231 cells Presented by Tadeja Snedec, University of Ljubljana, SLOVENIA
- 140 Unraveling Dual CCL21 Expression in Tumor and Serum: Enhancing Immunotherapy in Advanced Melanoma through Prospective Validation Presented by Carme Solé Blanch, Institut Germans Trias i Pujol, Badalona, SPAIN
- 141 Surface and soluble LILRB4 as a Prognostic Biomarker and Therapeutic Target in Chronic Lymphocytic Leukemia Presented by Christian Sordo Bahamonde, IUOPA and ISPA, Oviedo, SPAIN

- 142 Revealing resistance mechanisms to anti-PD1 therapy in primary and metastatic oral cancer using organoid technology Presented by Lili Szabo, University Hospital Würzburg and University of Würzburg, GERMANY
- 143 Immunoediting affects clonal evolution, mutational burden, and response to immunotherapy of replication repair-deficient cancers Presented by Uri Tabori, The Hospital for Sick Children and University of Toronto, Toronto, ON, CANADA
- 144 Fusobacterium nucleatum infection attenuates trastuzumab-mediated antibody-dependent cellular cytotoxicity in HER2+ OE19 gastroesophageal cancer cells. Presented by Muhammed Ashiq Thalappil, Dublin City University, IRELAND
- 145 Reshaping tumor microenvironment of Colorectal Cancer stem cells-derived xenografts with multikinase inhibitor Presented by Silvia Tomaino, Università Cattolica del Sacro Cuore, Roma, ITALY
- 146 Integrative molecular and spatial analysis of intratumoral tertiary lymphoid structures: insights into immunotherapy response Presented by Jana Tomankova, Sotio Biotech, Prague, CZECH REPUBLIC
- 147 Metabolic and Inflammatory Genes Associated with Therapy Failure in NSCLC Patients Treated with Immune Checkpoints Inhibitors Presented by Katiane Tostes, Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, BRAZIL
- 148 Stimulating resolution of inflammation to overcome CD8+ T cell exhaustion and boost immunotherapy Presented by Maria Tredicine, "G. d'Annunzio" University of Chieti, ITALY
- 149 Unveiling the Landscape of Tumor-Associated Myeloid Lectins in Immunosuppressive Breast Cancer Presented by Gonçalo Trindade, iBET and Universidade Nova de Lisboa, Oeiras, PORTUGAL
- 150 Exploring the impact of the fibrotic microenvironment on lung tumoral cells using a 3D multicellular spheroid model. Presented by Marina Tuxans Serrano, Germans Trias i Pujol Research Institute, Badalona, SPAIN
- 151 Experimental model of the mechanobiology of the immunocompetent tumor ecosystem Presented by Janet van der Graaf, IBEC and Universitat de Barcelona, Barcelona, SPAIN
- 152 Modulation of the immunogenicity of treatment-induced cancer cell death by DNASE1L3 Presented by Aliko Vasilakou, ImmunoConEpT, UMR CNRS 5164, Bordeaux, FRANCE
- 153 Dendritic cell boosting therapy for the treatment of Multiple Myeloma Presented by Emma Verheye, Vrije Universiteit Brussel and VIB Center for Inflammation Research, Brussels, BELGIUM
- 154 Identification of the Phosphatase CD45 as an Interactor and Modulator of the PD-1 Immune Receptor Presented by Giuseppe Vulcano, Istituto Superiore di Sanità and Università Cattolica del Sacro Cuore, Rome, ITALY
- 155 THSD4 is a novel mediator of T cell exclusion and anti-PD-1 response in breast cancer Presented by Olivia Walker, Dalhousie University, Halifax, Nova Scotia, CANADA
- 156 TGF- / NKX2-1 Regulation Signaling Promotes Chemokine Expression and Release to Modulate the Immune Microenvironment in Lung Cancer Presented by Mong-Lien Wang, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Beitou District, TAIWAN ROC
- 157 Exploring the Role of NRF2 in Immune Cell Infiltration Using an Organ-on-Chip Model Presented by Manolya Yildiz, Izmir Institute of Technology, Urla, Izmir, TURKEY
- 158 High grade serous ovarian cancer ascites polarises monocytes towards an immunosuppressive tumour associated macrophage phenotype Presented by Caitlin Waddell, University of Manchester, UK

Call for Content

More information: eacr.org/conferences/defenceisthebestattack2025/abstracts

Molecular Oncology, the affiliate journal of the European Association for Cancer Research (EACR), is launching a **new article collection within the 'Immuno-Oncology' thematic area**.

Molecular Oncology **EACR** European Association for Cancer Research



In line with the focus of the EACR conference, Defence is the Best Attack: Immuno-Oncology Breakthroughs, **we invite you to submit your latest research** on immune checkpoints, innate immune response, microbioma, immune cell therapies, vaccines, biomarkers of response and mechanisms of resistance to immunotherapy for cancer to *Molecular Oncology*.

Manuscripts may be submitted in the format of a Research Article, Short Report or Method. Review articles could be considered only after submitting a pre-submission inquiry to the *Molecular Oncology* editorial office (molonc@febs.org).

All manuscripts will undergo editorial assessment for novelty and completeness, followed by a standard peer review process. Accepted articles will be published continuously and prominently featured in an article collection on immuno-oncology. **Scan the QR code for further information and to begin your submission!**

We eagerly anticipate your valuable contributions to this special article collection, contributing to the ongoing advancement of cancer research.



Notes

Notes

Notes

Notes

Communication.
Collaboration.
Community.

EACR

European Association
for Cancer Research



**NOT A MEMBER
YET? JOIN NOW**

Apply for funding
to develop your
research &
expand
your
horizons



Benefit from
reduced
registration
rates at EACR
events

Join our online
networking
events



Build new
connections
with our 'Find a
Collaborator'
tool

Search
the EACR
Member
Network
and message
other members



Share your
perspective: write
for The Cancer
Researcher
magazine

Access
our free
expert
webinars on
research &
careers



Stay informed
with regular
updates on
news, jobs, and
conferences

Volunteer for
our Ambassador
Programme or
committees



QIAseq[®] – revealing the biological answers you seek



Your research quest is a complex, multi-faceted journey. Next-generation sequencing (NGS) can help you unlock intricate genomic and transcriptomic details.

Arm yourself with QIAseq NGS technologies to empower your journey from Sample to Insight[®].

Whether you're sequencing DNA or RNA, or even both, QIAseq NGS solutions provide:

- Accurate results from the most challenging of samples
- Streamlined, convenient and automation-friendly workflows
- Meaningful insights from NGS data with integrated bioinformatics
- Flexible customization and fast turnaround times

The secret lies in the sequence. Let QIAseq reveal the answers.



Discover more at www.qiagen.com/NGS



Trademarks: QIAGEN[®], Sample to Insight[®], QIAseq[®] (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. 05/2023 © 2023 QIAGEN, all rights reserved.

Ordering www.qiagen.com/shop | Technical Support www.support.qiagen.com | Website www.qiagen.com

Sample to Insight

EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the association to develop important initiatives.

